Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listi

Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.

Raccontata dabenzinga.com